Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2000-05-30
2009-02-24
Borin, Michael (Department: 1631)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S006120, C435S029000, C435S911000, C435S912000, C436S063000, C436S501000, C436S169000
Reexamination Certificate
active
07494768
ABSTRACT:
The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.
REFERENCES:
patent: 5631128 (1997-05-01), Kozal et al.
patent: 5650268 (1997-07-01), Kozal et al.
patent: 5856086 (1999-01-01), Kozal et al.
patent: 6221578 (2001-04-01), de Bethune et al.
patent: WO 97/27480 (1997-07-01), None
patent: WO 99/61658 (1999-12-01), None
patent: WO 99/61666 (1999-12-01), None
patent: WO 99/67427 (1999-12-01), None
patent: WO 00/78996 (2000-12-01), None
Jon H. Condra et al., Genetic Correlates of In Vivo Viral Resistance to Indinavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, Journal of Virology, Dec. 1996, p. 8270-8276.
Seki et al. Antiviral Chemistry & Chemotherapy (1995), 6(2), 73-9.
Bakhanashvili et al. Febs Letters (1996), 391(3), 257-262.
Larder et al. Abstr. Intersci Conf Antimicrob agents Chemother, Sep. 24, 1998; 38:28 (abstract No. LB-4).
Balotta et al., “Prevalence of Transmitted Nucleoside Analogue-Resistant HIV-1 Strains and Pre-Existing Mutations inpolReverse Transcriptase and Protease Region: Outcome After Treatment in Recently Infected Individuals,”Antiviral Therapy, 5, pp. 7-14 (2000).
Been-Tiktak et al., “In-Vitro Selection of HIV-1 Variants Resistant to Non-Nucleoside Reverse Transcriptase Inhibitors in Monocyte-Derived Macrophages,”Journal of Antimicrobial Chemotherapy, 40, pp. 847-853 (1997).
Catucci et al., “Development and Significance of the HIV-1 Reverse Transcriptase M184V Mutation During Combination Therapy with Lamivudine, Zidovudine, and Protease Inhibitors,”Journal of Acquired Immune Deficiency Syndromes, 21, pp. 203-208 (1999).
Coakley et al., “Phenotypic and Genotypic Resistance Patterns of HIV-1 Isolates Derived from Individuals Treated with Didanosine and Stavudine,”AIDS, 14, pp. F9-F15 (2000).
Descamps et al., “Susceptibility of Human Immunodeficiency Virus Type 1 Group O Isolates to Antiretroviral Agents: In Vitro Phenotypic and Genotypic Analyses,”Journal of Virology, pp. 8893-8898 (1997).
Edelstein et al., “Oligonucleotide Ligation Assay for Detecting Mutations in the Human Immunodeficiency Virus Type 1polGene That are Associated with Resistance to Zidovudine, Didanosine, and Lamivudine,”Journal of Clinical Microbiology, pp. 569-572 (1998).
Gunthard et al., “Human Immunodeficiency Virus Replication and Genotypic Resistance in Blood and Lymph Nodes After a Year of Potent Antiretroviral Therapy,”Journal of Virology, pp. 2422-2428 (1998).
Holodniy et al., “Human Immunodeficiency Virus Reverse Transcriptase Codon 215 Mutations Diminish Virologic Response to Didanosine-Zidovudine Therapy in Subjects with Non-Syncytium-Inducing Phenotype,”The Journal of Infectious Diseases, 174, pp. 854-857 (1996).
Hsu et al., Higher Fidelity of RNA-Dependent DNA Mispair Extension by M184V Drug-Resistant Than Wild-Type Reverse Transcriptase of Human Immunodeficiency Virus Type 1,Nucleic Acids Research, 25(22), pp. 4532-4536 (1997).
Ives et al., “Emergence of Resistant Variants of HIVin vitroDuring Monotherapy with the Proteinase Inhibitor Saquinavir,”Journal of Antimicrobial Chemotherapy, 39, pp. 771-779 (1997).
Kellam et al., Fifth Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Contributes to the Development of High-Level Resistance to Zidovudine,Proc. Natl. Acad. Sci. USA, 89, pp. 1934-1938 (1992).
Kemp et al., “A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and L-2′, 3′-Dideoxy-3′-Thiacytidine,”Journal of Virology, 72, pp. 5093-5098 (1998).
Larder et al., “Tipranavir Inhibits Broadly Protease Inhibitor-Resistant HIV-1 Clinical Samples,”AIDS, 14, pp. 1943-1948 (2000).
Mohamed et al. “The Sequential Occurrence ofpol215 andpol41 Zidovudine Resistance Mutations is Associated in an Additive Fashion with Low CD4 Cell Counts and High Plasma and Cellular HIV Viral Load,”Antiviral Research, 39, pp. 47-53 (1998).
Moyle, “Viral resistance Patterns Selected by Antiretroviral Drugs and Their Potential to Guide Treatment Choice,”Exp. Opin. Invest. Drugs, 6(8), pp. 943-964 (1997).
Nakano et al., Clonal Selection of HIV Type 1 Variants Associated with Resistance to Foscarnetin Vitro: Confirmation by Molecular Evolutionary Analysis,Aids Research and Human Reroviruses, 13(7), pp. 563-573 (1997).
Schmidt et al., “Simple Algorithm Derived from a Geno-/Phenotypic Database to Predict HIV-1 Protease Inhibitor Resistance,”AIDS, 14, pp. 1731-1738 (2000).
Shafer et al., “Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database,”Nucleic Acids Research, 28(1), pp. 346-348 (2000).
Tamalet et al., “Multidrug Resistance Genotypes (Insertions in the β3-β4 Finger Subdomain and MDR Mutations) of HIV-1 Reverse Transcriptase from Extensively Treated Patients: Incidence and Association with Other Resistance Mutations,”Virology, 270, 310-316 (2000).
Villahermosa et al., “Evaluation of Mixtures of Wild-Type HIV-1 and HIV-1 with Resistance Point Mutations Against Reverse Transcriptase Inhibitors,”Antiviral Therapy, 3, pp. 221-227 (1998).
Wegner et al., “Prevalence of Genotypic and Phenotypic Resistance to Anti-Retroviral Drugs in a Cohort of Therapy-Naïve HIV-1 Infected US Military Personnel,”AIDS, 14, pp. 1009-1015 (2000).
Angarano et al., “Genotype and Phenotype Resistance: An Overview,”Journal of Biological Regulators and Homeostatic Agents, 14, pp. 11-14 (2000).
Anton et al., “Comparative Patterns of HIV-1 Genotypic Resistance Profiles in Gut and Plasma,”3rdInt'l Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 86, vol. 4, Supp. 1 (1999).
Bethune et al., “Does Natural or Acquired Resistance to Reverse Transcriptase and Protease Inhibitors, Observed in HIV-1 Groups M (Subtypes A-H) and O, Differ from Subtype B,”3rdInt'l Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 49, vol. 4, Supp. 1 (1999).
Bloor et al., “Lamivudine-Resistant HIV-1 Clinical Isolates Lacking the MEt184Val Mutation have Novel Polymorphisms in RT,”3rdInt'l Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 25, vol. 4, Supp. 1 (1999).
Casado et al., “Rate of Non-nucleoside Reverse Transcriptase Inhibitor Resistance Among Patients Failing a Nevirapine Plus Protease Inhibitor-Containing Regimen,”3rdInt'l Workshop on HIV Drug Resistance and Treatment Strategies, Abstract 114, vol. 1, Supp. 1 (1999).
Calvez, V., “Resistance to Antiretroviral Drugs,”Antiviral Therapy, 3(4), pp. 5-7 (1998).
Chen et al., “Drug Resistance Mutations as Predictors of Phenotypic Zidovudine Resistance in HIV-1 infection,”AIDS, 11(12), pp. 1528-1529 (1997).
Condra et al., Genotypic or Phenotypic Susceptibility Testing May not Predict Clinical Responses to Indinavir,Antiviral Therapy, 1stInternational Workshop HIV Resistant Treatment Strategies and Eradication, Abstracts 47, pp. 48-49 (1997).
Condra, Jon H., “Resisting Resistance: Maximizing the Durability of Antiretroviral Therapy,”Annals of Internal Medicine, 128 (11) pp. 951-955 (1998).
D'Aquila, R.T., “HIV-1 Chemotherapy and Drug Resistance,”Clin. Diagnost. Virol, 3, 299
Hertogs Kurt
Larder Brendan
Pauwels Rudi
Borin Michael
Ren Yunling
Tibotec-Virco Virology BVBA
LandOfFree
Mutational profiles in HIV-1 protease and reverse... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutational profiles in HIV-1 protease and reverse..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutational profiles in HIV-1 protease and reverse... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4066498